LIVE WEBINAR

The Role of rhGH Therapy in Turner Syndrome (TS): Growth and Quality of Life







Thursday, 16 June 2022

From 13:00 to 14:00 CEST

SCIENTIFIC SEMINARS
INTERNATIONAL FOUNDATION

OVERVIEW

Turner Syndrome (TS) is a common genetic cause of short stature and ovarian insufficiency in young females, caused by loss of variable entity of an X chromosome. TS typically affects many aspects of patients' health, such as growth, fertility, metabolic and cardiovascular health among others. Short stature is one of the most common clinical characteristics in TS. When a reduction in growth velocity is witnessed, therapy with rhGH is approved by the FDA and EMA and can be attempted. Growth promoting therapy in TS has proven to increase final adult height to a variable extent, depending on treatment parameters (duration and dosage), young age at initiation and parental heights. If left untreated, adult TS patients show a mean reduction of about 20 cm compared to unaffected controls. Although the gain in height is well established during rhGH therapy, strong evidence-based data on when to start therapy is still missing. In this scenario, clinical observation and physician's experience make the difference and play a crucial role in initiating therapy at the appropriate age to maximize the auxological outcome. Normally, rhGH is initiated in a pharmacological dose regimen, with proven optimal safety profile. The aim of the growth promoting therapy is to attain a normal adult height for age, but also to ameliorate the quality of life of TS patients throughout the infancy and adolescence.

LEARNING OBJECTIVES

- Identify the best timing to start rhGH therapy in TS with growth impairment
- Evaluate and manage rhGH therapy in TS
- Recognize and avoid complications of rhGH in TS
- Maximize the results of rhGH therapy in terms of auxological and quality of life outcomes

TARGET AUDIENCE

Pediatricians, endocrinologists, general practitioners and nurses involved in the care of patients with TS.

LANGUAGE

English with simultaneous translation into Spanish and Korean.

For registration
CLICK HERE
REGISTRATION IS FREE OF CHARGE

CONTINUING MEDICAL EDUCATION

The Role of rhGH Therapy in Turner Syndrome (TS): Growth and Quality of Life", Rome, Italy, 16/06/2022-16/06/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1 European CME credit** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

CME PROVIDER

Scientific Seminars International Foundation
Program Manager: Annamaria Nesticò
annamaria.nestico@scientificseminars.com

Medical Advisor
Tommaso Todisco
Endocrinoloy Unit
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Italy



FACULTY

Margaret Boguszewski
Full Professor of Pediatrics
Federal University of Parana'
Department of Pediatrics
Curitiba, Brazil

Martin O. Savage
Emeritus Professor of Pediatric Endocrinology
The William Harvey Research Institute
Barts and the London School of Medicine & Dentistry, Queen Mary University of London
London, United Kingdom

Han-Wook Yoo
Professor, Department of Pediatrics,
Center for Genomic Medicine, CHA Bundang Medical Center
CHA University School of Medicine
Seongnam-si, Gyeonggi-do
Seul, Korea

THURSDAY, 16 JUNE 2022
from 13:00 to 14:00 CEST

		Chairman **Martin O. Savage, UK**
13.00		**Welcome and introduction** M. O. Savage (UK)
13.05		**Indications and initiation of rhGH therapy in TS** M. Boguszweski (Brazil)
13.25		**Key quality of life issues in childhood and benefits of rhGH therapy in TS** H.-W. Yoo (Korea)
13.45		**Q&A**
14.00		**End of the live webinar**

LEGEND

 Lecture;  Q&A General Discussion with participants

FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Margaret Boguszewski	Declared receipt of honoraria or consultation fees from Novo Nordisk, Pfizer, Sandoz, Merck Serono.
Martin O. Savage	Declared receipt of honoraria or consultation fees from OPKO, Pfizer, Sandoz, Merck Healthcare KGaA Darmstadt, Germany, Springer-Nature IME, Visen and participation in IPSEN and Novo Nordisk speaker's bureau.
Han-Wook Yoo	Declared no potential conflict of interest.

CHAIRMAN

Martin O. Savage

Martin O. Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He is a clinician with clinical and research interests in growth disorders, specifically those with abnormalities in the growth hormone-IGF-1 axis. His main research field has been the phenotype- genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other clinical interests are Cushing's syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. Professor Savage has lectured in 60 countries world-wide and has published more than 465 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. He continues to lecture nationally and internationally.

FACULTY

L1 Indications and initiation of rhGH therapy in TS

Margaret Boguszewski (Brazil)

Margaret Boguszewski

Medical training followed by Residency in Pediatrics, Residency in Pediatric Endocrinology and Master of Pediatric Endocrinology with the thesis:" Evaluation of the efficacy and safety of growth hormone therapy in short, prepubertal children, with chronic renal insufficiency" at the University Hospital, Federal University of Paraná, Curitiba, Brazil (1982-1993). Ph.D. in Pediatric Endocrinology at the International Paediatric Growth Research Centre, University of Göteborg, Göteborg, Sweden with the Thesis:" Short children born small for gestational age: Hormonal regulation of growth" (1993-1997). Currently is Full Professor of Pediatrics, Department of Pediatrics, Federal University of Paraná, Curitiba, Brazil; Member of the Board of Directors, The Growth Hormone Research Society; Member of the Editorial Board, Pituitary; Associate Editor, Frontiers in Endocrinology. Key publication in the field of growth, small for gestational age, growth hormone treatment and safety of growth hormone treatment.

L2 Key Quality of Life issues in childhood and benefits of rhGH therapy in TS

Han-Wook Yoo (Korea)

Han-Wook Yoo

Professor Yoo received his M.D. from the College of Medicine, Seoul National University in 1979. He has completed his clinical training as an internship and residency in 1983 and clinical fellowship in Pediatrics at Seoul National University Children's Hospital in 1986. He furthered his clinical and research training through a postdoctoral fellowship at Department of Pediatrics, Mount Sinai Medical Center, New York, U.S.A. from 1989 through 1992, and certified as clinical molecular geneticist by the American Board of Medical Genetics. In 1994, he joined the faculty of University of Ulsan College of Medicine, Asan Medical Center. In 2001, he became the Chief of the Department of Pediatrics. From 2009 through 2012, he has served as the president of Asan Medical Center Children's Hospital in Seoul, Korea. After retirement from Asan Medical Center in Feb.-2022, he continued his academic career at CHA Bundang Medical Center, CHA University School of Medicine as a professor of Pediatrics and Center for Genomic Medicine. Professor Yoo has published more than 250 peer-reviewed articles. He has received several awards for his research, and he is an active member of many international academic societies in the field of endocrinology and medical genetics. Professor Yoo's main research interests are focused on the characterization of molecular & functional defects of endocrine genetic disorders.



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.

Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com